Cardiol Therapeutics Inc.
@CardiolRx
Followers
5K
Following
2K
Media
214
Statuses
654
Heal the heart with innovative science. Clinical-stage life sciences company developing therapies for the treatment of heart disease NASDAQ $CRDL | TSX $CRDL
Toronto, Ontario
Joined May 2017
Watch @CardiolRx President/CEO, David Elsley, and CMO/Head of R&D, Andrew Hamer, participate in a Fireside Chat at the @CanaccordGenuity 45th Annual Growth Conference in Boston, MA. đź”˝Watch the Fireside Chat webcastđź”˝.
0
1
9
A live webcast of the Fireside Chat can be accessible through the following link: (. The replay will be available for 90 days following the conference.
0
0
5
We are pleased to announce that we will participate in a Fireside Chat at Canaccord Genuity’s 45th Annual Growth Conference in Boston, MA, on August 12, 2025, at 9:30 a.m. EDT. Please read the full press release ⬇️.
cardiolrx.com
Cardiol Therapeutics Inc. announced that it will participate in a Fireside Chat at Canaccord Genuity’s 45th Annual Growth Conference in Boston, MA, on August 12, 2025, at 9:30 a.m. EDT.
1
1
5
Today we announced the topline results from ARCHER, the Company’s Phase II clinical trial in patients with acute myocarditis. Please read the full press release ⬇️.
cardiolrx.com
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) today announced topline results from ARCHER, the Company’s Phase II clinical trial in patients with acute myocarditis.
5
2
16
We are pleased to announce database lock for ARCHER, the Phase II multi-national, randomized, double-blind, placebo-controlled trial investigating its lead asset, CardiolRx™, on myocardial recovery in patients with acute myocarditis. Please read the full press release ⬇️.
6
4
12
Today we announced the results from our Annual General Meeting of Shareholders held virtually via live audio webcast on May 28, 2025. Please read the full press release ⬇️.
cardiolrx.com
Toronto, ON – May 29, 2025 – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences company focused on developing anti-inflammatory and...
1
2
16
Today we announced the Company’s virtual Annual General Meeting of Shareholders will be webcast on May 28, 2025, at 4:30 p.m. EDT. Please read the full press release ⬇️.
cardiolrx.com
Additional information about the AGM, including details on how to participate and vote, is available on the Company’s website at cardiolrx.com/investors/events-presentations/.
0
1
9
Our ongoing clinical trials of CardiolRx™ for myocarditis (ARCHER) and pericarditis (MAVERIC) are featured in @myocarditisfndn, highlighting our commitment to developing innovative treatments for patients affected by these debilitating heart conditions.
myocarditisfoundation.org
Cardiol Therapeutics' ARCHER and MAVERIC clinical trials show promise for treating myocarditis and recurrent pericarditis, offering new hope for patients.
1
3
21
RT @myocarditisfndn: There are many things happening in the world of myocarditis and pericarditis, and all of them are looking very positiv….
0
3
0
#Pericarditis is a painful heart condition that can keep coming back. In a new @PatientWorthy article, our CMO Dr. Andrew Hamer shares insights on recurrent pericarditis, current treatments & why more options are needed. Read more:#RareDisease #HeartHealth.
0
3
14
We are pleased to announce that pharmaceutical industry veteran Dr. Timothy J. Garnett, has been nominated to stand for election to the Company’s Board of Directors at its 2025 AGM to be held on May 28, 2025. Please read the full press release ⬇️.
cardiolrx.com
Cardiol Therapeutics Inc. today announced that pharmaceutical industry veteran Timothy J. Garnett, M.D., has been nominated to stand for election to the Company’s Board of Directors at its 2025...
1
3
15
Why heart attacks are rising in young adults—and what to watch out for, via @NatGeo . Research shows that heart attacks are becoming more prevalent among adults younger than 50—and the outcomes are worse for women.
nationalgeographic.com
Research shows that heart attacks are becoming more prevalent among adults younger than 50—and the outcomes are worse for women. The good news is we know how to prevent them.
1
3
13
We are pleased to announce that Northwestern University has enrolled the first patient in the pivotal Phase III MAVERIC trial evaluating our lead drug candidate CardiolRx™ for the prevention of recurrent pericarditis. Please read the full press release ⬇️.
0
4
18
CardiolRx™ granted U.S. FDA Orphan Drug Designation for the treatment of pericarditis, which includes recurrent pericarditis. Cash and cash equivalents of $30.6 million as of December 31, 2024, to fund operations into Q3 2026.
0
0
7
Completed patient enrollment in the Phase II ARCHER trial evaluating CardiolRx™ in patients with acute myocarditis, with topline data expected in Q2 2025.
1
0
7
Key Highlights include:.Reported positive data from the Phase II MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis; results support advancing to the Phase III MAVERIC trial.
1
0
3
We are pleased to announce today our year-end 2024 update on operations. Please read the full press release ⬇️.
cardiolrx.com
Cardiol Therapeutics Inc. announced today its year-end 2024 update on operations following the filing of its audited Financial Statements and Management’s Discussion and Analysis for the year ended...
1
2
23
We are pleased to announce we will present at the TD Cowen 45th Annual Health Care Conference in Boston, MA, on March 5, 2025, at 11:10 a.m. EST. Please read the full press release ⬇️.
cardiolrx.com
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) will present at the TD Cowen 45th Annual Health Care Conference in Boston, MA, on March 5, 2025, at 11:10 a.m. EST.
0
2
10
Today is #RareDiseaseDay! A global initiative to bring attention to the experiences of individuals and caregivers navigating rare diseases. 1/10 Americans is living with a rare disease &Â worldwide, there are +300 million people with rare diseases. #Pericarditis #Myocarditis
5
1
8
We are pleased to announce publication of research in the Journal of the American College of Cardiology: Basic to Translational Science that supports development of its proprietary subcutaneous drug candidate, CRD-38, for the treatment of heart failure. Please read the full.
0
5
13